187 related articles for article (PubMed ID: 23957630)
21. Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
Chakraborty R; Mukkamalla SK; Singam K; Calderon N
Korean J Intern Med; 2014 Nov; 29(6):827-9. PubMed ID: 25378984
[No Abstract] [Full Text] [Related]
22. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Ichim CV
Stem Cells Transl Med; 2014 Apr; 3(4):405-15. PubMed ID: 24598782
[TBL] [Abstract][Full Text] [Related]
23. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
24. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M; Soverini S; De Benedittis C
Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
[TBL] [Abstract][Full Text] [Related]
25. BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
Leonetti F; Stefanachi A; Nicolotti O; Catto M; Pisani L; Cellamare S; Carotti A
Curr Med Chem; 2011; 18(19):2943-59. PubMed ID: 21651486
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
27. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
Bavaro L; Martelli M; Cavo M; Soverini S
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817512
[TBL] [Abstract][Full Text] [Related]
28. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.
Valent P; Deininger M
Leuk Lymphoma; 2008 Apr; 49(4):604-9. PubMed ID: 18398718
[TBL] [Abstract][Full Text] [Related]
29. The second generation of BCR-ABL tyrosine kinase inhibitors.
Tauchi T; Ohyashiki K
Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
Cui J; Zhu Z; Liu S; Li Q; Meng L; Cheng H; Zhong Z; Li W; You Y; Zhu X; Zou P
Leuk Lymphoma; 2018 Sep; 59(9):2264-2266. PubMed ID: 29334838
[No Abstract] [Full Text] [Related]
31. Novel strategies to eradicate resistant cells in chronic myeloid leukemia.
Schoepf AM; Gust R
Future Med Chem; 2020 Dec; 12(23):2089-2092. PubMed ID: 33228384
[No Abstract] [Full Text] [Related]
32. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.
Baccarani M; Gale RP
Leukemia; 2021 Aug; 35(8):2199-2204. PubMed ID: 34002028
[No Abstract] [Full Text] [Related]
33. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutic approaches in chronic myeloid leukemia.
Özgür Yurttaş N; Eşkazan AE
Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP; Mauro MJ
Hematol Oncol Clin North Am; 2017 Aug; 31(4):577-587. PubMed ID: 28673389
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
Bixby D; Talpaz M
Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
[TBL] [Abstract][Full Text] [Related]
37. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
Engel NW; Constantin A; Fowlkes S; Assouline S
J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
[No Abstract] [Full Text] [Related]
38. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
39. [Pharmacology profile and clinical findings of bosutinib hydrate (Bosulif® Tablets)].
Tahara M; Shibata A; Katsura S
Nihon Yakurigaku Zasshi; 2016 May; 147(5):311-8. PubMed ID: 27181728
[No Abstract] [Full Text] [Related]
40. Getting to the stem of chronic myeloid leukaemia.
Savona M; Talpaz M
Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]